2.3 Intracellular carnitine and derivatives The concentrations of carnitine, -butyrobetaine (BB), trimethyllysine (TML) and acetlycarnitine were determined in PBMC and erythrocyte lysate by tandem mass spectrometry according to Hirche et al
Weight loss by timeframe Month 1-2 (initial titration): 5-10 lbs lost Lower doses, body adapting Some appetite suppression Establishing habits Month 3-4 (dose escalation): 10-20 lbs total lost Significant appetite reduction Noticeable changes Plateau possible, keep titrating Month 5-8 (approaching maintenance dose): 20-35 lbs total lost Near or at full dose Maximum appetite suppression Consistent weekly loss (1-3 lbs) Month 9-12 (maintenance dose): 30-50 lbs total lost Full dose combination Continued steady loss Body composition improving Month 12-18 (long-term): 40-60+ lbs total lost (or 15-25% body weight) Exceptional responders: 60-80 lbs Weight stabilizing Focus shifts to maintenance Individual variation: Starting weight matters (higher = more absolute loss) Metabolism, activity level, diet affect results Some lose faster, some slower Consistency most important Comparison to semaglutide monotherapy Semaglutide 2.4mg alone (typical): 6 months: 20-30 lbs 12 months: 30-40 lbs 18 months: 35-45 lbs Average: 10-15% body weight CagriSema combination (typical): 6 months: 25-40 lbs 12 months: 40-60 lbs 18 months: 50-70+ lbs Average: 15-25% body weight Additional benefit: 50-75% more weight loss with combination Example: 240 lb person Semaglutide alone: Lose 24-36 lbs 204-216 lbs CagriSema combo: Lose 36-60 lbs 180-204 lbs Clinically significant difference See our peptides before and after results and how long do peptides take to work
Glossary PCOS Polycystic ovary syndrome HPOA Hypothalamic-pituitary-ovarian Axis OHSS Ovarian hyperstimulation syndrome IR Insulin resistance LH Luteinizing hormone HA Hyperandrogenemia PCOM Polycystic ovarian morphology FSH Follicle-stimulating hormone COC Combined oral contraceptives FGCs Follicular granulosa cells mTOR mammalian target of rapamycin GDF-9 Growth Differentiation Factor 9 BMP-15 Bone morphogenetic protein 15 TGF- Transforming growth factor- NADPH Nicotinamide adenine dinucleotide phosphate MMP Matrix metalloproteinase AMPK Adenosine monophosphate-activated protein kinase miRNAs Micro RNAs GLUT4 Glucose transporter protein 4 P-GP P-glycoprotein PDGF Platelet-derived growth factor CTGF-1 Connective tissue growth factor 1 PI3K/AKT Phosphatidylinositol 3-kinase/protein kinase LIF/STAT3 Leukemia inhibitory factor/signal transduction ROS Reactive Oxygen Species PP Precocious pubarche P4 Progesterone E2 Estradiol HOXA10 Homology box A10 BP Bee pollen OCT Organic cation transporter IGF-1 Insulin-like growth factor-1 MATEs Multidrug toxin extrusion proteins PGR Progesterone AGEs Advanced glycation end products RAGE Receptor for advanced glycation end product NF-B Nuclear factor kappa B LPS Lipopolysaccharide ITGB3 Integrin beta-3 GLM Glucose-lipid metabolism EDV Endothelium-dependent vasodilation LBW Low birth weight AUB Abnormal uterine bleeding GDM Gestational diabetes mellitus BMI Body mass index PMAT Plasma membrane monoamine transporter RSA Recurrent spontaneous abortion mTORC1 mammalian target of the rapamycin complex 1 ATP Adenosine triphosphate MASLD Metabolic dysfunction-associated steatotic liver disease EC Endometrial cancer MS Metabolic syndrome NR4A1 Nuclear receptor LKB1 Liver Kinase B1 FA Fatty acid ALT Aminotransferase GGT Gamma-glutamyl transferase References 1 AbdellatifM.SedejS.Carmona-GutierrezD.MadeoF.KroemerG
L.AlexeyevM
Some individuals have experienced gallbladder problems, including an increased risk of gallstones
UpToDate: Infertility treatment with gonadotropins (Beyond the Basics)
